The Role of Gut Microbiota in Various Neurological and Psychiatric Disorders—An Evidence Mapping Based on Quantified Evidence

Zang, Yaning; Lai, Xigui; Li, Conghui; Ding, Dongfang; Wang, Ying; Zhu, Yi

doi:https://doi.org/10.1155/2023/5127157

Mediators of Inflammation

On this page

Abstract Introduction Methods Results Discussion Conclusion Data Availability Disclosure Conflicts of Interest Authors’ Contributions Acknowledgments Supplementary Materials References Copyright Related Articles

Special Issue

The Role of Inflammation Mediators in Neurological Diseases

View this Special Issue

Review Article | Open Access

Volume 2023 | Article ID 5127157 | https://doi.org/10.1155/2023/5127157

The Role of Gut Microbiota in Various Neurological and Psychiatric Disorders—An Evidence Mapping Based on Quantified Evidence

Yaning Zang,¹Xigui Lai,²Conghui Li,^3,4Dongfang Ding,^3,4Ying Wang,⁵and Yi Zhu^3,4

Academic Editor: Feng Zhang

Received13 Jun 2022

Revised21 Sept 2022

Accepted10 Oct 2022

Published08 Feb 2023

Abstract

Background and Object. There is a growing body of evidence highlighting the significant role of gut microbiota in various neurological and psychiatric disorders. We performed an evidence mapping to review the association between different microbiota and these disorders and assessed the strength of evidence for these associations. Methods. We searched PubMed, Cochrane Library, and Epistemonikos to identify systematic reviews and meta-analysis (SRs). We searched for neurological diseases and psychiatric disorders, including Alzheimer’s disease (AD), attention deficit hyperactivity disorder (ADHD), amyotrophic lateral sclerosis (ALS), autism spectrum disorder (ASD), anorexia nervosa (AN), bipolar disorder (BD), eating disorder (ED), generalized anxiety disorder (GAD), major depressive disorder (MDD), multiple sclerosis (MS), obsessive compulsive disorder (OCD), Parkinson’s disease (PD), posttraumatic stress disorder (PTSD), spinal cord injury (SCI), schizophrenia, and stroke. We used A Measurement Tool to Assess Systematic Reviews (AMSTAR-2) to evaluate the quality of included SRs. We also created an evidence map showing the role of gut microbiota in neurological diseases and the certainty of the evidence. Results. In total, 42 studies were included in this evidence mapping. Most findings were obtained from observational studies. According to the AMSTAR-2 assessment, 21 SRs scored “critically low” in terms of methodological quality, 16 SR scored “low,” and 5 SR scored “moderate.” A total of 15 diseases have been investigated for the potential association between gut microbiome alpha diversity and disease, with the Shannon index and Simpson index being the most widely studied. A total of 12 diseases were investigated for potential link between beta diversity and disease. At the phylum level, Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Verrucomicrobia were more researched. At the genus level, Prevotella, Coprococcus, Parabacteroides, Phascolarctobacterium, Escherichia Shigella, Alistipes, Sutteralla, Veillonella, Odoribacter, Faecalibacterium, Bacteroides, Bifidobacterium, Dialister, and Blautia were more researched. Some diseases have been found to have specific flora changes, and some diseases have been found to have common intestinal microbiological changes. Conclusion. We found varied levels of evidence for the associations between gut microbiota and neurological diseases; some gut microbiota increased the risk of neurological diseases, whereas others showed evidence of benefit that gut microbiota might be promising therapeutic targets for such diseases.

1. Introduction

The intestinal flora mainly exists in the digestive tract and is an important part of the human microbiome. Intestinal flora is characterized by abundant species and large quantity, and the functional potential of different intestinal flora is increasingly understood. Intestinal flora can not only help the body to decompose and store fat but also regulate the immune, endocrine, metabolic, and neurological functions through immune, neuroendocrine, and vagus nerves. Therefore, the occurrence of various diseases of the human body is closely related to the disorder of intestinal flora, such as obesity [1], cardiovascular diseases [2], kidney diseases [3], and nervous system diseases [4].

Studies have found that there are channels in the human body that connect nerves between the gut and the brain, which is known as the microbiota-gut-brain axis [5]. The gut microbiota can regulate neuroinflammation and gastrointestinal symptoms through the gut-brain axis, which has a significant impact on the neurological function of the body not only through the secretion of neurotransmitters but also through immunity and synapses [6]. And, previous studies have shown that inflammatory bowel disease (IBD) patients often suffer from anxiety and depression, which may be associated with impaired brain structure and function and changes in gut microbiome [7–9].

Indeed, since each person features a unique microbiota composition, some systematic review and meta-analysis (SRs) have investigated differences in the composition of the gut microbiota between patients with neurological and psychiatric disorders and healthy individuals [10–12]. For instance, neurogenic bowel dysfunction frequently occurs in patients with spinal cord injury (SCI) and multiple sclerosis (MS) patients who were found to have similar or lower alpha diversity compared to healthy controls [13]. However, SRs tend to focus on specific diseases, such as Parkinson’s disease (PD), autism spectrum disorder (ASD), and stroke. To provide an overview of a research area, a novel approach to evidence synthesis research called evidence mapping has been developed [14, 15]. The characteristic of evidence mapping method is that SRs are used as the unit of analysis to extract and classify data, A Measurement Tool to Assess Systematic Reviews (AMSTAR-2) was used to evaluate the credibility of evidence, and it is presented in visual charts.

Therefore, the aim of this evidence mapping was to summarize the gut microbiota associated with neurological and psychiatric disorders and to identify common or differential gut microbiota present in different neurological and psychiatric disorders. Such associations may afford opportunities for both understanding aetiology and making targeted treatment strategies, including probiotic supplements, dietary changes, and even fecal microbial transplants (FMT).

2. Methods

2.1. Study Design

To summarize the associations of gut microbiota with neurological or psychiatric disorders on a larger scale, we used evidence mapping. This study was conducted on the basis of the methodology proposed by global evidence mapping [16]. The study process was divided into four phases: (1) search strategy and selection, (2) study quality assessment, (3) data extraction, and (4) data synthesis and analysis.

2.2. Search Strategy and Selection

A systematic search of the literature was conducted in PubMed, Embase, Cochrane Library, and Epistemonikos databases up to March 21, 2022. Medical subject heading (MeSH) terms and keywords used in the search included various neurological diseases and psychiatric disorders, gastrointestinal microbiome, gut-brain axis, enteric nervous system, and meta-analysis or systematic review. Search results were independently reviewed for eligibility by two independent researchers (Yaning Zang and Ying Wang), with discrepancies resolved by a third researcher (Yi Zhu). Studies were included based on the following criteria (Table 1). Furthermore, the reference list of the relevant reviews has been screened to identify potential studies. Details of the search strategy are provided in Supplementary Material 1.

2.3. Study Quality Assessment

The quality of included studies was assessed using the AMSTAR-2 tool, which uses 16 items (critical items: 2, 4, 7, 9, 11, 13, and 15) to assess the methodological quality of systematic reviews or meta-analysis. For each item, there are three answers: yes, partially yes, no. Studies were rated in four categories: “high,” no critical weakness and no more than one noncritical weakness; “moderate,” no critical weakness and more than one noncritical weakness; “low,” one critical flaw with or without noncritical weaknesses; and “critically low,” more than one critical flaw with or without noncritical weaknesses. The evaluation results were presented through heat maps. Two reviewers (Yaning Zang and Xigui Lai) independently evaluated each study and rated the studies according to the AMSTAR-2 tool. Discrepancies in risk assessment were resolved by consensus and, if required, consultation with a third reviewer (Yi Zhu).

2.4. Data Extraction

Two reviewers (Yaning Zang and Dongfang Ding) independently extracted data using a predesigned table included: the author and year, study design included in this paper, search date of included study, study design and number of studies included in SRs, sample of SRs, flora sample, methods of microbiology assessment, participants type, diversity indices included and diversity indices of the microbiome, and gut microbiota’s taxonomic composition at different levels, such as phylum, order, family, genus, and species.

2.5. Data Synthesis and Analysis

Studies included in this paper reported the comparison of gut microbiota between patients and controls, including alpha diversity, beta diversity, and the relative abundance of bacteria of different phylum, class, order, families, genus, and species. Evidence mapping was used to compare the different microbiota involved in the studies’ pathologies. The evidence mapping displayed information in two dimensions: (1) The different colors show changes in the abundance of the flora in neurological or psychiatric disorders which included increase, decrease, significant difference, no difference, mixed, and unclear. It should be noted that when different studies show inconsistent changes in the microbiome, it was classified as mixed. (2) The different shapes in the cells indicate the strength of the evidence.

3. Results

3.1. Selected Studies

In total, 42 studies were included in this evidence mapping. A flow diagram of study selection is presented in Figure 1.

3.2. Methodological Quality of Included Studies

According to the AMSTAR-2 criteria, 21 SRs [7, 17–36] scored “critically low,” 16 SR [13, 37–51] scored “low,” and 5 SR [36, 52–55] scored “moderate” (Figure 2). The most frequent drawbacks were as follows: no mentioning of the protocol in the systematic overview, no description of the rationale for the study designs included in the review, and no statement of funding for the included studies. The detailed assessments process is provided in Supplementary Material 2.

3.3. Characteristics of the Included Studies

The earliest articles included in this paper are from 2018. From 2018 forward, the number of studies in this field increased rapidly. Most of the primary studies were observational, including cohort studies, case-control studies, and case series. For the studies that used marker-gene analysis, 16S ribosomal RNA was the most amplified gene (Table 2).

The most studied neuropsychiatric disorder is autism spectrum disorder (ASD) with 11 studies [29, 30, 32, 34, 42, 46, 49–51, 53, 55] included in this paper. 3 SRs included Alzheimer’s disease (AD) [31, 40, 41], 10 SRs included attention deficit hyperactivity disorder (ADHD) [17, 19, 22, 37, 39, 45, 46, 49, 51, 53], 1 SR included amyotrophic lateral sclerosis (ALS) [21], 2 SRs included anorexia nervosa (AN) [36, 45], 5 SRs included bipolar disorder (BD) [20, 43, 45, 46, 52], 1 SR included eating disorder (ED) [27], 2 SRs included generalized anxiety disorder (GAD) [45, 46], 9 SRs included major depressive disorder (MDD) [20, 23, 26, 28, 33, 45, 46, 52, 56], 3 SRs included multiple sclerosis (MS) [13, 25, 54], 1 SR included obsessive compulsive disorder (OCD) [45], 6 SRs included Parkinson’s disease (PD) [7, 25, 27, 35, 44, 47], 2 SRs included posttraumatic stress disorder (PTSD) [45, 46], 2 SRs included spinal cord Injury (SCI) [13, 38], 5 SRs included schizophrenia [20, 45, 46, 48, 52], and 2 SRs included stroke [18, 24].

3.4. Specific Findings from the Evidence Mapping

Figure 3 summarizes the outcomes of the included studies on microbiota profiles (alpha and beta diversity) and gut microbiota taxa. Studies included in this evidence mapping reported the comparison of gut microbiota between patients and controls, including alpha diversity, beta diversity, and the relative abundance of bacteria of different phylum, class, order, family, genus, and species.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

Figure 3

Evidence mapping of microbiome changes. Abbreviations: AD: Alzheimer’s disease, ADHD: attention deficit hyperactivity disorder, ALS: amyotrophic lateral sclerosis, ASD: autism spectrum disorder, AN: anorexia nervosa, BD: bipolar disorder, ED: eating disorder; GAD: generalized anxiety disorder, MDD: major depressive disorder, MS: multiple sclerosis, OCD: obsessive compulsive disorder, PD: Parkinson’s disease, PTSD: posttraumatic stress disorder, SCI: spinal cord injury, SCZ: schizophrenia. (a) Diversity. (b) Phylum level. (c) Class level. (d) Order level. (e) Family level. (f) Genus level. (g) Species level.

A total of 15 diseases have been investigated for the potential association between gut microbiome alpha diversity and disease, with the Shannon index and Simpson index being the most widely studied. A total of 12 diseases were investigated for potential link between beta diversity and disease. The Bray-Curtis distance, weighted UniFrac distances, and unweighted UniFrac distances were the most widely examined. Regarding the microbiota assessment, it is the most classified the bacteria detected according to both phylum and genus, with a wide variety of bacteria being studied. Few studies included the level of species when classifying the bacteria detected. At the phylum level, 5 phyla were more identified: Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Verrucomicrobia. At the genus level, 14 genera were more identified: Prevotella, Coprococcus, Parabacteroides, Phascolarctobacterium, Escherichia Shigella, Alistipes, Sutteralla, Veillonella, Odoribacter, Faecalibacterium, Bacteroides, Bifidobacterium, Dialister, and Blautia.

In particular, some diseases have been found to have specific flora changes. At the phylum level, Coriobacteriaceae was only observed in AN patients, and Deferribacter, Lactobacillale, and Tropheryma were only observed in SCZ patients. At the order level, Alteromonadales, Bifidonbacteriales, Coriobacteriales, Cytophagales, Deltaproteobacteria, Eerysipelotrichales, Flavobacteriales, Pasteurellales, and Sphingobacteriales were only observed in MDD patients, and Desulfovibrio was only observed in stroke patients. At the family level, Acidaminococcaceae, Bifidobacteriaceae, Nocardiaceae, Tannerellaceae, and Thermoanaerobacteriaceae were only observed in MDD patients, Catabacteriaceae, Enterococcaceae, and Xanthomonadaceae were only observed in ADHD patients, Flavobacteriaceae and Helicobacteraceae were only observed in stroke patients, Pasteurellaceae was only observed in SCZ patients, and Sutterellaceae was only observed in ASD patients. At the genus level, Acetanaerobacterium, Burkholderia, and lkaliflexus were only observed in ASD patients, Kineothrix was only observed in ALS patients, Bulleidia, Butyricicoccus, Olsenella, Oxalobacter, Paraprevotella, and Parvimonas were only observed in MDD patients, Butyricicoccus was only observed in stroke patients, and Pseudomonas was only observed in MS patients. At the species level, Acidovorax was only observed in stroke patients, Bacteroides caccae, Bacteroides coprocola, Bacteroides ovatus, Bacteroides uniformis, Collinsella, Gemmiger, Lachnospiraceae, Lachnospiraceae, Lachnospiraceae, Streptococcus, Streptococcus, Uricibacter, and Veillonella parvula were only observed in ADHD patients, Bacteroidetes genera, Desulfovibrio, Devosia, Dialister invisus, Dialister invisus, and Dialister invisus were only observed in ASD patients.

Although different studies draw many inconsistent conclusions, we found some overlaps between certain diseases when comparing the direction of association. At the phylum level, the most consistent change of ADHD, AN, and BD was the increase of Actinobacteria. The most consistent change of AD, ADHD, ALS, GAD, and MDD was the depletion of Firmicutes. At the genus level, the consistent change of ALS, MS, SCI, and stroke was the increase of Akkermansia and the increase of Bacteroides in ADHD, AN, GAD, MS, and SCI patients.

4. Discussion

4.1. Main Findings

In conclusion, our findings are as follows: first, studies on gut microbiomes among individuals with SCI, stroke, and AD are limited. The gastrointestinal symptoms (GI), such as diarrhea, constipation, and abdominal pain, inflammatory bowel disease, and irritable bowel syndrome (IBS) are often comorbid with SCI, stroke, AD, and so on. The simultaneous occurrence of neurological, psychiatric, and gastrointestinal diseases increases the risk of disease progression and poor outcomes, and the treatment of one disease can reverse the risk of another disease [5, 57]. There are still many gaps in whether modification of the gut microbiota can reduce the risk of these diseases or improve patient health.

Second, we found evidence of disease specificity, suggesting that these microbiota may be involved in the pathogenesis. And, identifying biotypes may provide opportunities to make targeted treatment strategies in clinic, including probiotic supplements, dietary changes, and even fecal microbial transplants (FMT). For example, Lactobacillus rhamnosus as a therapeutic supplement can reduce the risk of neuropsychiatric disorders in infants with autism spectrum disorders [58]. In a variety of animal models, Lactobacillus and Bifidobacterium can reduce the occurrence of anxiety and depression-related symptoms and positively affect memory, learning and cognition [59]. Nutritional deficiency due to inadequate intake or absorption is a recognized risk factor for neuropsychiatric diseases. For example, the content of folic acid and vitamin B12 in the blood of schizophrenic patients decreases and is related to the severity of symptoms [60]. Increase the intake of vegetables and fruits, restore the level of vitamin B in the body, and help to reduce and reverse some symptoms of neuropsychiatric diseases. Research found that a high-fat diet can significantly increase the deposition of amyloid protein and significantly increase the incidence of AD [61]. FMT infuses the fecal filtrate of healthy people into the intestines of patients with intestinal or neurological disorders to increase the number of beneficial bacteria and reduce the number of harmful bacteria in patients to maintain the steady state of gut microbiota [62, 63]. Neurologic dysfunction and autistic symptoms were significantly improved after FMT treatment in patients with MS and children with ASD [64].

Third, certain diseases have similar patterns of microbial changes. Specifically, we observed that ADHD, AN, and BD; AD, ADHD, ALS, GAD, and MDD; ALS, MS, SCI, and stroke; and ADHD, AN, GAD, MS, and SCI overlapped in the categories of changes in abundance, suggesting that these overlaps may be related to transdiagnostic of pathophysiology. There are several possible explanations for the mechanisms that drive the gut microbiota to affect different neurological and psychiatric disorders [6, 65, 66]: (1) Intestinal lymphocytes can feel the changes of gut microbiota, release endocrine or paracrine cytokines, and then act on the central nervous system; (2) intestinal peptide released by intestinal endocrine cells can stimulate sensory nerve endings, produce nerve impulses, and transmit them to the brain; and (3) microbial metabolites can act as neurotransmitters or their precursors on intestinal epithelial cells with endocrine or paracrine effects. Afferent stimuli relay through the brain stem and reach the visceral sensory higher center composed of amygdala and insula. For example, study [67] reported that the feces of PD patients had significantly reduced Clostridium, and the content of short chain fatty acids (SCFA) was significantly lower than that of healthy people, indicating that the intestinal ecological imbalance of PD patients was related to the decrease of SCFA level; then, the reduction of SCFA can promote α. The accumulation of synuclein in the intestinal nervous system leads to PD [68]. Although it is uncertain whether the change of intestinal flora is the cause or result of PD, gut microbiota can indeed lead to intestinal dysfunction and intestinal inflammation cascade through the interaction of intestinal epithelial barrier, immune system, and intestinal nervous system vagal pathway and then induce the loss of neuronal function [69].

Finally, it is worth noting that systematic reviews included in our study summarized differences in gut microbiota between the patients group and healthy group and draw a conflicting or even opposite conclusion, which may suggest the excess or dearth of a microbe may lead to deranged pathophysiology, so any microbe if not present in suitable amounts may be harmful [5]. Another reason for the nonsignificant difference may be that the observation of these studies is time limited. For example, after SCI, a new intestinal environment may allow new species to proliferate for a period of time, but in the end, these exceed the dominant species, resulting in a lack of changes in species abundance distribution.

4.2. Limitations and Further Direction

Due to the limitations of the included studies, we did not conduct analyses of sampling method, sampling time, sequencing, or analysis pipelines. Given that most findings were obtained from observational studies cannot infer causality or explain temporal changes in gut microbiota, so the possibility of reverse causality should be taken into account.

Another point that needs to be emphasized is that this article mainly analyzes the changes of single flora. Some studies have shown that the use of probiotics or probiotics may improve the symptoms of patients with neurological or mental disorders. In further research, we will analyze the effects of different probiotics, diets, and flora transplantation on patients to find the optimal combination of flora.

5. Conclusion

Analyzing the changes in the microbiome could be an essential source of knowledge for better understanding neurological or psychiatric disorders. Some diseases have specific flora changes, while others have consistent changes. Although the exact mechanism of action is unclear, regulating gut microbiota and maintaining physical stability and health by improving diet, supplementing special probiotics and probiotics, or FMT transplantation can open up new ideas for the treatment of neurological and mental diseases.

Data Availability

All data supporting the conclusions of this study are included in the appendix.

Disclosure

The data being presented in the journal has not been published elsewhere in whole. The authors agree to publish the work in the Mediators of Inflammation.

Conflicts of Interest

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contributions

Study concept, design, and supervision were done by Yi Zhu and Yaning Zang. Study screening and data extraction were done by Yaning Zang and Ying Wang. Article quality assessment was done by Yaning Zang and Xigui Lai. Data extraction and analysis were done by Yaning Zang and Dongfang Ding. Drafting of the manuscript was done by Yaning Zang. Revision of the manuscript was done by Yi Zhu and Yaning Zang. All authors have edited, reviewed, and approved the final version of the manuscript.

Acknowledgments

This work was supported by the National Natural Science Foundation of China Project (No. 81860875).

Supplementary Materials

Supplementary 1. Database search strategies.

Supplementary 2. AMSTAR-2 assessment.

References

A. Asadi, N. Shadab Mehr, M. H. Mohamadi et al., “Obesity and gut–microbiota–brain axis: a narrative review,” Journal of Clinical Laboratory Analysis, vol. 36, no. 5, article e24420, 2022.
View at: Publisher Site | Google Scholar
K. Pontes, M. R. Guedes, M. R. D. Cunha et al., “Effects of probiotics on body adiposity and cardiovascular risk markers in individuals with overweight and obesity: a systematic review and meta-analysis of randomized controlled trials,” Clinical Nutrition, vol. 40, no. 8, pp. 4915–4931, 2021.
View at: Publisher Site | Google Scholar
S. Chung, J. L. Barnes, and K. S. Astroth, “Gastrointestinal microbiota in patients with chronic kidney disease: a systematic review,” Advances in Nutrition, vol. 10, no. 5, pp. 888–901, 2019.
View at: Publisher Site | Google Scholar
L. Morvan, C. de Sequeira, C. Hengstberger, P. Enck, and I. Mack, “Effect of probiotics on psychiatric symptoms and central nervous system functions in human health and disease: a systematic review and meta-analysis,” Nutrients, vol. 14, no. 3, 2022.
View at: Google Scholar
A. Azhari, F. Azizan, and G. Esposito, “A systematic review of gut-immune-brain mechanisms in autism spectrum disorder,” Developmental Psychobiology, vol. 61, no. 5, pp. 752–771, 2019.
View at: Publisher Site | Google Scholar
B. Vafadari, “Stress and the role of the gut-brain axis in the pathogenesis of schizophrenia: a literature review,” International Journal of Molecular Sciences, vol. 22, no. 18, p. 9747, 2021.
View at: Publisher Site | Google Scholar
S. Romano, G. M. Savva, J. R. Bedarf, I. G. Charles, F. Hildebrand, and A. Narbad, “Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation,” NPJ Parkinson’s Disease, vol. 7, no. 1, p. 27, 2021.
View at: Publisher Site | Google Scholar
K. M. Fairbrass, J. Lovatt, B. Barberio, Y. Yuan, D. J. Gracie, and A. C. Ford, “Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis,” Gut, vol. 71, no. 9, pp. 1773–1780, 2022.
View at: Publisher Site | Google Scholar
B. Barberio, M. Zamani, C. J. Black, E. V. Savarino, and A. C. Ford, “Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis,” The Lancet Gastroenterology & Hepatology, vol. 6, no. 5, pp. 359–370, 2021.
View at: Publisher Site | Google Scholar
M. Hirayama and K. Ohno, “Parkinson’s disease and gut microbiota,” Annals of Nutrition & Metabolism, vol. 77, Supplement 2, pp. 28–35, 2021.
View at: Publisher Site | Google Scholar
P. Angoorani, H. S. Ejtahed, S. D. Siadat, F. Sharifi, and B. Larijani, “Is there any link between cognitive impairment and gut microbiota? A systematic review,” Gerontology, vol. 68, pp. 1201–1213, 2022.
View at: Publisher Site | Google Scholar
L. Al-Ayadhi, N. Zayed, R. S. Bhat, N. M. S. Moubayed, M. N. Al-Muammar, and A. El-Ansary, “The use of biomarkers associated with leaky gut as a diagnostic tool for early intervention in autism spectrum disorder: a systematic review,” Gut Pathogens, vol. 13, no. 1, p. 54, 2021.
View at: Publisher Site | Google Scholar
W. Faber, J. Stolwijk-Swuste, F. van Ginkel et al., “Faecal microbiota in patients with neurogenic bowel dysfunction and spinal cord injury or multiple sclerosis-a systematic review,” Journal of Clinical Medicine, vol. 10, no. 8, p. 1598, 2021.
View at: Publisher Site | Google Scholar
Y. Zang, Y. Zhang, X. Lai et al., “Repetitive transcranial magnetic stimulation for neuropathic pain on the non-motor cortex: an evidence mapping of systematic reviews,” Evidence-based Complementary and Alternative Medicine, vol. 2021, Article ID 3671800, 16 pages, 2021.
View at: Publisher Site | Google Scholar
Y. Zang, Y. Zhang, X. Lai et al., “Evidence mapping based on systematic reviews of repetitive transcranial magnetic stimulation on the motor cortex for neuropathic pain,” Frontiers in Human Neuroscience, vol. 15, article 743846, 2022.
View at: Publisher Site | Google Scholar
P. Bragge, O. Clavisi, T. Turner, E. Tavender, A. Collie, and R. L. Gruen, “The global evidence mapping initiative: scoping research in broad topic areas,” BMC Medical Research Methodology, vol. 11, no. 1, p. 92, 2011.
View at: Publisher Site | Google Scholar
A. Payen, M. J. Chen, T. G. Carter, R. P. Kilmer, and J. M. Bennett, “Childhood ADHD, going beyond the brain: a meta-analysis on peripheral physiological markers of the heart and the gut,” Frontiers in Endocrinology, vol. 13, article 738065, 2022.
View at: Publisher Site | Google Scholar
G. Guido, E. Crivellaro, G. De Fortunato, and L. Melloni, “Sex and age dimorphism of the gut-brain axis in ischemic stroke: a systematic review of preliminary studies,” Brain Research, vol. 1784, article 147888, 2022.
View at: Publisher Site | Google Scholar
D. Gkougka, K. Mitropoulos, G. Tzanakaki et al., “Gut microbiome and attention deficit/hyperactivity disorder: a systematic review,” Pediatric Research, vol. 92, no. 6, pp. 1507–1519, 2022.
View at: Publisher Site | Google Scholar
N. Vindegaard, H. Speyer, M. Nordentoft, S. Rasmussen, and M. E. Benros, “Gut microbial changes of patients with psychotic and affective disorders: a systematic review,” Schizophrenia Research, vol. 234, pp. 1–10, 2021.
View at: Publisher Site | Google Scholar
J. Sun, T. Huang, J. W. Debelius, and F. Fang, “Gut microbiome and amyotrophic lateral sclerosis: a systematic review of current evidence,” Journal of Internal Medicine, vol. 290, no. 4, pp. 758–788, 2021.
View at: Publisher Site | Google Scholar
A. C. Sukmajaya, M. I. Lusida, Soetjipto, and Y. Setiawati, “Systematic review of gut microbiota and attention-deficit hyperactivity disorder (ADHD),” Annals of General Psychiatry, vol. 20, no. 1, p. 12, 2021.
View at: Publisher Site | Google Scholar
C. A. Simpson, C. Diaz-Arteche, D. Eliby, O. S. Schwartz, J. G. Simmons, and C. S. M. Cowan, “The gut microbiota in anxiety and depression - a systematic review,” Clinical Psychology Review, vol. 83, article 101943, 2021.
View at: Publisher Site | Google Scholar
V. Sharma, V. Sharma, S. Shahjouei et al., “At the intersection of gut microbiome and stroke: a systematic review of the literature,” Frontiers in Neurology, vol. 12, article 729399, 2021.
View at: Publisher Site | Google Scholar
J. Plassais, G. Gbikpi-Benissan, M. Figarol et al., “Gut microbiome alpha-diversity is not a marker of Parkinson’s disease and multiple sclerosis,” Brain communications, vol. 3, no. 2, 2021.
View at: Publisher Site | Google Scholar
J. K. Knudsen, C. Bundgaard-Nielsen, S. Hjerrild, R. E. Nielsen, P. Leutscher, and S. Sørensen, “Gut microbiota variations in patients diagnosed with major depressive disorder-a systematic review,” Brain and Behavior: A Cognitive Neuroscience Perspective, vol. 11, no. 7, article e02177, 2021.
View at: Google Scholar
R. M. Tucker, A. D. Augustin, B. H. Hayee et al., “Role of Helicobacters in neuropsychiatric disease: a systematic review in idiopathic parkinsonism,” Journal of Clinical Medicine, vol. 9, no. 7, p. 2159, 2020.
View at: Publisher Site | Google Scholar
K. Sanada, S. Nakajima, S. Kurokawa et al., “Gut microbiota and major depressive disorder: a systematic review and meta-analysis,” Journal of Affective Disorders, vol. 266, pp. 1–13, 2020.
View at: Publisher Site | Google Scholar
L. Iglesias-Vázquez, R. G. Van Ginkel, V. Arija, and J. Canals, “Composition of gut microbiota in children with autism spectrum disorder: a systematic review and meta-analysis,” Nutrients, vol. 12, no. 3, p. 792, 2020.
View at: Publisher Site | Google Scholar
L. K. H. Ho, V. J. W. Tong, N. Syn et al., “Gut microbiota changes in children with autism spectrum disorder: a systematic review,” Gut Pathogens, vol. 12, no. 1, p. 6, 2020.
View at: Publisher Site | Google Scholar
M. Doulberis, G. Kotronis, D. Gialamprinou et al., “Alzheimer’s disease and gastrointestinal microbiota; impact of Helicobacter pylori infection involvement,” The International Journal of Neuroscience, vol. 131, no. 3, pp. 1–19, 2021.
View at: Google Scholar
N. Bezawada, T. H. Phang, G. L. Hold, and R. Hansen, “Autism spectrum disorder and the gut microbiota in children: a systematic review,” Annals of Nutrition & Metabolism, vol. 76, no. 1, pp. 16–29, 2020.
View at: Publisher Site | Google Scholar
Z. A. Barandouzi, A. R. Starkweather, W. A. Henderson, A. Gyamfi, and X. S. Cong, “Altered composition of gut microbiota in depression: a systematic review,” Frontiers in Psychiatry, vol. 11, p. 541, 2020.
View at: Publisher Site | Google Scholar
M. Xu, X. Xu, J. Li, and F. Li, “Association between gut microbiota and autism spectrum disorder: a systematic review and meta-analysis,” Frontiers in Psychiatry, vol. 10, p. 473, 2019.
View at: Publisher Site | Google Scholar
J. M. Boertien, P. A. B. Pereira, V. T. E. Aho, and F. Scheperjans, “Increasing comparability and utility of gut microbiome studies in Parkinson’s disease: a systematic review,” Journal of Parkinson's Disease, vol. 9, no. s2, pp. S297–s312, 2019.
View at: Publisher Site | Google Scholar
H. F. Schwensen, C. Kan, J. Treasure, N. Høiby, and M. Sjögren, “A systematic review of studies on the faecal microbiota in anorexia nervosa: future research may need to include microbiota from the small intestine,” Eating and Weight Disorders, vol. 23, no. 4, pp. 399–418, 2018.
View at: Publisher Site | Google Scholar
N. Wang, X. Gao, Z. Zhang, and L. Yang, “Composition of the gut microbiota in attention deficit hyperactivity disorder: a systematic review and meta-analysis,” Front Endocrinol, vol. 13, article 838941, 2022.
View at: Publisher Site | Google Scholar
E. Valido, A. Bertolo, G. P. Fränkl et al., “Systematic review of the changes in the microbiome following spinal cord injury: animal and human evidence,” Spinal Cord, vol. 60, no. 4, pp. 288–300, 2022.
View at: Publisher Site | Google Scholar
S. Shirvani-Rad, H. S. Ejtahed, F. Ettehad Marvasti et al., “The role of gut microbiota-brain axis in pathophysiology of ADHD: a systematic review,” Journal of Attention Disorders, vol. 26, no. 13, pp. 1698–1710, 2022.
View at: Publisher Site | Google Scholar
C. C. Hung, C. C. Chang, C. W. Huang, R. Nouchi, and C. H. Cheng, “Gut microbiota in patients with Alzheimer’s disease spectrum: a systematic review and meta-analysis,” Aging, vol. 14, no. 1, pp. 477–496, 2022.
View at: Publisher Site | Google Scholar
E. M. González Cordero, M. Cuevas-Budhart, D. Perez-Moran, M. A. Trejo Villeda, and M. G. Gª-Madrid, “Relationship between the gut microbiota and Alzheimer’s disease: a systematic review,” Journal of Alzheimer's Disease, vol. 87, no. 2, pp. 519–528, 2022.
View at: Publisher Site | Google Scholar
P. Andreo-Martínez, M. Rubio-Aparicio, J. Sánchez-Meca, A. Veas, and A. E. Martínez-González, “A meta-analysis of gut microbiota in children with autism,” Journal of Autism and Developmental Disorders, vol. 52, no. 3, pp. 1374–1387, 2022.
View at: Publisher Site | Google Scholar
M. E. Sublette, S. Cheung, E. Lieberman et al., “Bipolar disorder and the gut microbiome: a systematic review,” Bipolar Disorders, vol. 23, no. 6, pp. 544–564, 2021.
View at: Publisher Site | Google Scholar
T. Shen, Y. Yue, T. He et al., “The association between the gut microbiota and Parkinson’s disease, a meta-analysis,” Frontiers in Aging Neuroscience, vol. 13, article 636545, 2021.
View at: Publisher Site | Google Scholar
V. L. Nikolova, M. R. B. Hall, L. J. Hall, A. J. Cleare, J. M. Stone, and A. H. Young, “Perturbations in gut microbiota composition in psychiatric disorders: a review and meta-analysis,” JAMA Psychiatry, vol. 78, no. 12, pp. 1343–1354, 2021.
View at: Publisher Site | Google Scholar
L. L. Chen, A. Abbaspour, G. F. Mkoma, C. M. Bulik, C. Rück, and D. Djurfeldt, “Gut microbiota in psychiatric disorders: a systematic review,” Psychosomatic Medicine, vol. 83, no. 7, pp. 679–692, 2021.
View at: Publisher Site | Google Scholar
N. D. Nuzum, A. Loughman, E. A. Szymlek-Gay, A. Hendy, W. P. Teo, and H. Macpherson, “Gut microbiota differences between healthy older adults and individuals with Parkinson’s disease: a systematic review,” Neuroscience and Biobehavioral Reviews, vol. 112, pp. 227–241, 2020.
View at: Publisher Site | Google Scholar
A. K. Kraeuter, R. Phillips, and Z. Sarnyai, “The gut microbiome in psychosis from mice to men: a systematic review of preclinical and clinical studies,” Frontiers in Psychiatry, vol. 11, p. 799, 2020.
View at: Publisher Site | Google Scholar
C. Bundgaard-Nielsen, J. Knudsen, P. D. C. Leutscher et al., “Gut microbiota profiles of autism spectrum disorder and attention deficit/hyperactivity disorder: a systematic literature review,” Gut Microbes, vol. 11, no. 5, pp. 1172–1187, 2020.
View at: Publisher Site | Google Scholar
A. E. Martínez-González and P. Andreo-Martínez, “The role of gut microbiota in gastrointestinal symptoms of children with ASD,” Medicina, vol. 55, no. 8, p. 408, 2019.
View at: Publisher Site | Google Scholar
E. Lacorte, G. Gervasi, I. Bacigalupo, N. Vanacore, U. Raucci, and P. Parisi, “A systematic review of the microbiome in children with neurodevelopmental disorders,” Frontiers in Neurology, vol. 10, p. 727, 2019.
View at: Publisher Site | Google Scholar
A. J. McGuinness, J. A. Davis, S. L. Dawson et al., “A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia,” Molecular Psychiatry, vol. 27, no. 4, pp. 1920–1935, 2022.
View at: Publisher Site | Google Scholar
L. Jurek, M. Sevil, A. Jay et al., “Is there a dysbiosis in individuals with a neurodevelopmental disorder compared to controls over the course of development? A systematic review,” European Child & Adolescent Psychiatry, vol. 30, no. 11, pp. 1671–1694, 2021.
View at: Publisher Site | Google Scholar
A. Mirza, J. D. Forbes, F. Zhu et al., “The multiple sclerosis gut microbiota: a systematic review,” Multiple Sclerosis and Related Disorders, vol. 37, article 101427, 2020.
View at: Publisher Site | Google Scholar
F. Liu, J. Li, F. Wu, H. Zheng, Q. Peng, and H. Zhou, “Altered composition and function of intestinal microbiota in autism spectrum disorders: a systematic review,” Translational Psychiatry, vol. 9, no. 1, p. 43, 2019.
View at: Publisher Site | Google Scholar
S. G. Cheung, A. R. Goldenthal, A. C. Uhlemann, J. J. Mann, J. M. Miller, and M. E. Sublette, “Systematic review of gut microbiota and major depression,” Frontiers in Psychiatry, vol. 10, p. 34, 2019.
View at: Publisher Site | Google Scholar
B. M. Arneth, “Gut-brain axis biochemical signalling from the gastrointestinal tract to the central nervous system: gut dysbiosis and altered brain function,” Postgraduate Medical Journal, vol. 94, no. 1114, pp. 446–452, 2018.
View at: Publisher Site | Google Scholar
A. Pärtty, M. Kalliomäki, P. Wacklin, S. Salminen, and E. Isolauri, “A possible link between early probiotic intervention and the risk of neuropsychiatric disorders later in childhood: a randomized trial,” Pediatric Research, vol. 77, no. 6, pp. 823–828, 2015.
View at: Publisher Site | Google Scholar
M. F. Sun, Y. L. Zhu, Z. L. Zhou et al., “Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson’s disease mice: gut microbiota, glial reaction and TLR4/TNF-α signaling pathway,” Brain, Behavior, and Immunity, vol. 70, pp. 48–60, 2018.
View at: Publisher Site | Google Scholar
J. Firth, B. Stubbs, J. Sarris et al., “The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis,” Psychological Medicine, vol. 47, no. 9, pp. 1515–1527, 2017.
View at: Publisher Site | Google Scholar
J. Lof, K. Smits, V. Melotte, and L. E. Kuil, “The health effect of probiotics on high-fat diet-induced cognitive impairment, depression and anxiety: a cross-species systematic review,” Neuroscience and Biobehavioral Reviews, vol. 136, article 104634, 2022.
View at: Publisher Site | Google Scholar
A. Chinna Meyyappan, E. Forth, C. J. K. Wallace, and R. Milev, “Effect of fecal microbiota transplant on symptoms of psychiatric disorders: a systematic review,” BMC Psychiatry, vol. 20, no. 1, p. 299, 2020.
View at: Publisher Site | Google Scholar
M. Madsen, N. Kimer, F. Bendtsen, and A. M. Petersen, “Fecal microbiota transplantation in hepatic encephalopathy: a systematic review,” Scandinavian Journal of Gastroenterology, vol. 56, no. 5, pp. 560–569, 2021.
View at: Publisher Site | Google Scholar
T. J. Borody, L. J. Brandt, and S. Paramsothy, “Therapeutic faecal microbiota transplantation: current status and future developments,” Current Opinion in Gastroenterology, vol. 30, no. 1, pp. 97–105, 2014.
View at: Publisher Site | Google Scholar
A. Beopoulos, M. Gea, A. Fasano, and F. Iris, “Autonomic nervous system neuroanatomical alterations could provoke and maintain gastrointestinal dysbiosis in autism spectrum disorder (ASD): a novel microbiome-host interaction mechanistic hypothesis,” Nutrients, vol. 14, no. 1, p. 65, 2022.
View at: Publisher Site | Google Scholar
T. Knuesel and M. H. Mohajeri, “The role of the gut microbiota in the development and progression of major depressive and bipolar disorder,” Nutrients, vol. 14, no. 1, p. 37, 2022.
View at: Publisher Site | Google Scholar
M. M. Unger, J. Spiegel, K. U. Dillmann et al., “Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls,” Parkinsonism & Related Disorders, vol. 32, pp. 66–72, 2016.
View at: Publisher Site | Google Scholar
X. Y. Qin, S. P. Zhang, C. Cao, Y. P. Loh, and Y. Cheng, “Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis,” JAMA Neurology, vol. 73, no. 11, pp. 1316–1324, 2016.
View at: Publisher Site | Google Scholar
S. F. Santos, H. L. de Oliveira, E. S. Yamada, B. C. Neves, and A. Pereira Jr., “The gut and Parkinson’s disease-a bidirectional pathway,” Frontiers in Neurology, vol. 10, p. 574, 2019.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2023 Yaning Zang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1577

Downloads

1749

Citations